BR112023026258A2 - Terapia genética para esclerose tuberosa - Google Patents
Terapia genética para esclerose tuberosaInfo
- Publication number
- BR112023026258A2 BR112023026258A2 BR112023026258A BR112023026258A BR112023026258A2 BR 112023026258 A2 BR112023026258 A2 BR 112023026258A2 BR 112023026258 A BR112023026258 A BR 112023026258A BR 112023026258 A BR112023026258 A BR 112023026258A BR 112023026258 A2 BR112023026258 A2 BR 112023026258A2
- Authority
- BR
- Brazil
- Prior art keywords
- gene therapy
- tuberous sclerosis
- methods
- compositions
- aav
- Prior art date
Links
- 208000026911 Tuberous sclerosis complex Diseases 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 title abstract 3
- 208000009999 tuberous sclerosis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
- C07K14/4706—Guanosine triphosphatase activating protein, GAP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163210456P | 2021-06-14 | 2021-06-14 | |
| PCT/US2022/033452 WO2022266113A1 (en) | 2021-06-14 | 2022-06-14 | Gene therapy for tuberous sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023026258A2 true BR112023026258A2 (pt) | 2024-02-27 |
Family
ID=83080777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023026258A BR112023026258A2 (pt) | 2021-06-14 | 2022-06-14 | Terapia genética para esclerose tuberosa |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240261439A1 (https=) |
| EP (1) | EP4355766A1 (https=) |
| JP (1) | JP2024522943A (https=) |
| CN (1) | CN117715928A (https=) |
| BR (1) | BR112023026258A2 (https=) |
| CA (1) | CA3223219A1 (https=) |
| WO (1) | WO2022266113A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| WO2004058166A2 (en) | 2002-12-23 | 2004-07-15 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US7561973B1 (en) | 2008-07-31 | 2009-07-14 | Dna Twopointo, Inc. | Methods for determining properties that affect an expression property value of polynucleotides in an expression system |
| US7561972B1 (en) | 2008-06-06 | 2009-07-14 | Dna Twopointo, Inc. | Synthetic nucleic acids for expression of encoded proteins |
| EP3624856B1 (en) | 2017-05-17 | 2024-04-03 | The General Hospital Corporation | Gene therapy for tuberous sclerosis |
-
2022
- 2022-06-14 CN CN202280050778.6A patent/CN117715928A/zh active Pending
- 2022-06-14 JP JP2024520657A patent/JP2024522943A/ja active Pending
- 2022-06-14 EP EP22760803.1A patent/EP4355766A1/en active Pending
- 2022-06-14 WO PCT/US2022/033452 patent/WO2022266113A1/en not_active Ceased
- 2022-06-14 CA CA3223219A patent/CA3223219A1/en active Pending
- 2022-06-14 BR BR112023026258A patent/BR112023026258A2/pt unknown
- 2022-06-14 US US18/570,040 patent/US20240261439A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3223219A1 (en) | 2022-12-22 |
| US20240261439A1 (en) | 2024-08-08 |
| WO2022266113A1 (en) | 2022-12-22 |
| EP4355766A1 (en) | 2024-04-24 |
| CN117715928A (zh) | 2024-03-15 |
| JP2024522943A (ja) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
| BR112021020957A2 (pt) | Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea | |
| MX2021013420A (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica. | |
| BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
| BR112022022644A2 (pt) | Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas | |
| BR112022000724A2 (pt) | Proteínas de capsídeo de aav modificado para tratamento de doença artrítica | |
| CL2022000939A1 (es) | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c | |
| BR112021016570A2 (pt) | Entrega de vetor de vírus adenoassociado de beta-sarcoglicano e tratamento de distrofia muscular | |
| WO2020219766A8 (en) | Compositions useful in treatment of rett syndrome | |
| BR112022004027A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| BR112023019056A2 (pt) | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte | |
| BR112022023908A2 (pt) | Composições de vírus adenoassociados para restauração da função do gene pah e métodos de uso das mesmas | |
| CO2024010847A2 (es) | Construcciones de vectores para la distribución de ácidos nucleicos que codifican anticuerpos terapéuticos anti-igf-1r y métodos para usarlos | |
| BR112021023473A2 (pt) | Vetores de terapia genética para osteopetrose maligna infantil | |
| BR112021020706A2 (pt) | Métodos e composições para expressão de transgene | |
| CO2024013743A2 (es) | Terapia génica dirigida para la distrofia miotónica dm-1 | |
| CL2025002985A1 (es) | Composiciones y métodos para tratar trastornos de la deficiencia de proteína de unión a sintaxina1 | |
| WO2023004407A3 (en) | Adeno-associated virus compositions and methods of use thereof | |
| CO2025004844A2 (es) | Vectores de aav recombinantes para tratamiento de distrofia muscular | |
| BR112023026258A2 (pt) | Terapia genética para esclerose tuberosa | |
| UY39426A (es) | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela) con aav-mir-sod1 | |
| CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
| JOP20240034A1 (ar) | بروتين كابسيد vp1 معدل مفصول يخص الفيروس aav9 | |
| BR112022019182A2 (pt) | Composições de vírus adeno-associadas para transferência do gene ids e métodos de uso da mesma | |
| AR134214A1 (es) | Redireccionamiento de cápsides de aav para dirigirlas al sistema nervioso central |